|Systematic (IUPAC) name|
(13-ethyl-17-ethynyl-3-hydroxyimino- 1,2,6,7,8,9,10,11,12,14,15,16- dodecahydrocyclopenta[a] phenanthren-17-yl) acetate
|Biological half-life||12–30 hours|
|CAS Registry Number|
|ATC code||G03 G03 (only combinations with estrogens)|
|Molecular mass||369.497 g/mol|
|(what is this?)|
Norgestimate (INN, USAN, BAN) is an acetylated progestin used as an oral contraceptive. It acts as a prodrug to norelgestromine (17-deacetylnorgestimate or levonorgestrel 3-oxime), the primary active metabolite, and levonorgestrel (deacetylation of norgestimate occurs in the intestines and the liver). Unlike levonorgestrel, norgestimate shows high selectivity for the progesterone receptor and weak androgenic action due to a large drug-induced elevation in the level of sex hormone-binding globulin (SHBG) (which preferentially binds androgens and thus inhibits their action). In accordance, clinical trials have observed minimal androgenic side effects. Norgestimate and its metabolites themselves, unlike many other progestins, do not bind to SHBG. Norgestimate is used in combination with ethinyl estradiol as an oral contraceptive.
- Thomas L. Lemke; David A. Williams (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1316–. ISBN 978-0-7817-6879-5.
- Chapdelaine A, Desmarais JL, Derman RJ (1989). "Clinical evidence of the minimal androgenic activity of norgestimate". Int. J. Fertil. 34 (5): 347–52. PMID 2571595.
- : Ortho Tri-Cyclen
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|